ReviewCurrent opinion in molecular therapeutics2010
Cancer therapy with bispecific antibodies: Clinical experience.
Review in Current opinion in molecular therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics.Antibodies (Basel, Switzerland) · 2021Review
- DNA-Mediated Assembly of Multispecific Antibodies for T Cell Engaging and Tumor Killing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Multiplexed Targeting of Barrett's Neoplasia with a Heterobivalent Ligand: Imaging Study on Mouse Xenograft in Vivo and Human Specimens ex Vivo.Journal of medicinal chemistry · 2018Article
- Bispecific antibodies in cancer immunotherapy.Therapeutic advances in vaccines and immunotherapy · 2018Review
- Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.Scientific reports · 2017Article
- Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Immunotherapy · 2016Review
- In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy.BMC bioinformatics · 2016Article
- Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Synthetic biology approaches to engineer T cells.Current opinion in immunology · 2015Review
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics.Bioscience reports · 2015Review
- Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done.Expert opinion on biological therapy · 2015Article
- Article
- Article
- Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.Angewandte Chemie (International ed. in English) · 2014Article
- A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy.Oncotarget · 2014Article
- Design and applications of bispecific heterodimers: molecular imaging and beyond.Molecular pharmaceutics · 2014Review
- Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.Bone marrow transplantation · 2014Article
- Cytokine-induced killer cells promote antitumor immunity.Journal of translational medicine · 2013Review
- Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.BMC cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The binding of at least two molecular targets simultaneously with a single bispecific antibody is an attractive concept. The use of bispecific antibodies as possible therapeutic agents for cancer treatment was proposed in the mid-1980s. The design and production of bispecific antibodies using antibody- and/or receptor-based platform technology has improved significantly with advances in the knowledge of molecular manipulations, protein engineering techniques, and the expression of antigens and receptors on healthy and malignant cells. The common strategy for making bispecific antibodies involves combining the variable domains of the desired mAbs into a single bispecific structure. Many different formats of bispecific antibodies have been generated within the research field of bispecific immunotherapeutics, including the chemical heteroconjugation of two complete molecules or fragments of mAbs, quadromas, F(ab')2, diabodies, tandem diabodies and single-chain antibodies. This review describes key modifications in the development of bispecific antibodies that can improve their efficacy and stability, and provides a clinical perspective on the application of bispecific antibodies for the treatment of solid and liquid tumors, including the promises and research limitations of this approach.
Indexed as
Identifiers
20521223PMC3785321W1513884174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.